Forest Takes On Merck, Novartis In Hypertension; Benicar Another Lexapro?
Forest/Sankyo's Benicar is rivaling Novartis' Diovan in the number of new patient starts in the angiotensin II inhibitor antihypertensive class, Forest President Kenneth Goodman told the Friedman Billings Ramsey growth conference June 2 in New York
You may also be interested in...
Forest Labs is not putting any "impediments" in the way of generic applications for the antidepressant Celexa (citalopram), President Kenneth Goodman told the Friedman Billings Ramsey growth conference June 2 in New York
Novartis has the support of HHS and the Centers for Medicare & Medicaid Services for its hypertension disease awareness campaign
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011